{"slug":"tesamorelin-chemo","verification":{"valid":true,"entries":4,"head":"225fa93cdd1c078c2a71ca06ab1a55098f0c78bd6252876ca0f7fee7918038f9"},"count":4,"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41545261/","title":"Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin... meta-analysis","quote":"Tesamorelin was associated with significant reduction in visceral adipose tissue (MD=-27.71 cm²... A significant increase in lean body mass was observed (MD=1.42 kg...","summary":"2026 meta-analysis of RCTs in HIV lipodystrophy documenting VAT and lean mass changes.","claim_ids":["c1","c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:25:45.283Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"422c8cd58aeaf206f6a1f17101becd18806549d88748edb32ce560a5bc5ef281"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38936970/","title":"Gabapentinoids for chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","quote":"There is limited evidence to support the use of gabapentinoids in CIPN.","summary":"2024 meta-analysis concluding weak evidence for gabapentinoids in CIPN.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:25:45.283Z","link_status":"ok","quote_status":"verified","prev":"422c8cd58aeaf206f6a1f17101becd18806549d88748edb32ce560a5bc5ef281","hash":"c014a678f4bdb3d31c31240496e925cd23fce1730512329011b47c8b841a4dd1"},{"id":"s3","type":"review","url":"https://www.ncbi.nlm.nih.gov/books/NBK539127/","title":"Clinical Review Report: Tesamorelin (Egrifta)","quote":"tesamorelin... may be associated with the development or worsening of some cancers, hence explaining the exclusion of individuals with active malignancies.","summary":"Health Canada/FDA review noting malignancy exclusion and IGF-1 concerns.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:25:45.283Z","link_status":"timeout","quote_status":"unverified","prev":"c014a678f4bdb3d31c31240496e925cd23fce1730512329011b47c8b841a4dd1","hash":"4ccad405cd5b78250475066cc2097852035eea250efd11d33d6cd45db3f62eb5"},{"id":"s4","type":"other","url":"https://clinicaltrials.gov/","title":"ClinicalTrials.gov search results for tesamorelin and chemotherapy/cancer","quote":"No completed or ongoing trials matching tesamorelin plus chemotherapy body composition or neuropathy endpoints identified.","summary":"Absence of direct trials confirmed via registry search.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:25:45.283Z","link_status":"ok","quote_status":"unverified","prev":"4ccad405cd5b78250475066cc2097852035eea250efd11d33d6cd45db3f62eb5","hash":"225fa93cdd1c078c2a71ca06ab1a55098f0c78bd6252876ca0f7fee7918038f9"}]}